This toolkit has been developed to guide medication review and encourage appropriate prescribing. It is divided into three sections (see Toolkit contents below) and features validated tools.
Appropriate prescribing encompasses both the under-prescribing of beneficial medicines and over-prescribing of medicines.
Polypharmacy refers to the use of multiple medication items by one person at the same time. There is no universally accepted definition for polypharmacy, and multiple definitions are used. The most commonly cited definition is five or more medicines used daily, but it can range from two or more to 11 or more medicines. Numerical-only definitions fail to recognise specific co-morbidities, so a more useful definition is ‘the use of medicines that are not clinically indicated’.
Polypharmacy may be beneficial (appropriate polypharmacy) or potentially harmful (inappropriate or problematic polypharmacy):
- Appropriate polypharmacy is prescribing for an individual for complex conditions or for multiple conditions in circumstances where medicines use has been optimised and where the medicines are prescribed according to best evidence.
- Inappropriate polypharmacy is prescribing multiple medicines inappropriately, or where the intended benefit of the medication is not realised. Inappropriate prescribing includes over-prescribing, under-prescribing and mis-prescribing (eg, a prescribing error).
Adverse drug events
As people age, the body’s ability to handle medicines changes. For example, reduced renal and hepatic function reduce the clearance (leaving the body) of medicines (pharmacokinetics changes), and there are changes in sensitivity to medicines (altered pharmacodynamics). These changes, and increasing use of medicines, make people aged 65 years of age or older more susceptible to the adverse effects of medicines. We know that the more medicines a patient is prescribed the greater the risk of drug interactions and adverse drug reactions. The risk of an adverse drug event has been estimated at 13 percent for two drugs, 58 percent for five drugs and 82 percent for seven or more (see Figure 1). Minimising the number of medicines prescribed reduces the risk of patient harm through adverse drug events and drug–drug interactions.
Deprescribing describes the process of stopping, stepping down, or reducing doses of unnecessary or (potentially) harmful medicines, with the goal of improving patient outcomes and quality of life. The tools below can help prescribers decide which medicines may be inappropriate, by helping balance the benefits and risks from medicines, and to guide medicines review for an individual patient. The tools are generally targeted at the older person who may be living with several long-term conditions, often compounded by disability and/or frailty, but they apply to any adult patient.
Tools to guide medication review
Many different tools exist that highlight potentially inappropriate prescribing. The most commonly cited are Beers and the STOPP/START criteria. Many are variants of the Beers list (not listed here).
The tools in this toolkit are only a guide to medication review. The risks of polypharmacy must be balanced with the potential benefit(s) from a medicine. The criteria must be applied at an individual level as part of any risk-benefit analysis: what matters to the patient, the patient’s comorbidities, frailty, life expectancy and medicine interactions. In practice, two or three tools may be combined to inform a medication review (eg, Beers plus the Medication Appropriateness Index).
- The American Geriatrics Society (AGS) Beers Criteria (the Beers list)
- NO TEARS
- Drug burden index (DBI)
- Anticholinergic cognitive burden scale (ACB)/anticholinergic risk scale (ARS)
- Medication appropriateness index (MAI)
- Medication appropriateness tool for co-morbid health conditions in dementia (Match-D)
- Australian prescribing indicators tool
- Masoon N, Shakib S, Kalisch-Ellett, et al. 2017. What is polypharmacy? A systematic review of definitions. BMC Geriatrics 17: 230–9.
- Fulton MM, Allen ER. 2005. Polypharmacy in the elderly: a literature review. Journal of the American Academy of Nurse Practitioners. 17(4): 123–32.
- Duerden M, Avery T, Payne R. 2013. Polypharmacy and medicines optimisation. Making it safe and sound. The King’s Fund. London.
- Shi S, Mörike K, Klotz U. 2008. The clinical implications of ageing for rational drug therapy. Review. Eur J Clin Pharmacol 64: 183–99.
- 2019 American Geriatrics Society. 2019. Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 67: 674–94.
- O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2.
- Hanlon JT, Schmader KE, Smasa GP, et al. 1992. A method for assessing drug therapy appropriateness. J Clin Epidemiol 45(10): 1045–51.